Annovis Bio (ANVS) Stock Surge Following Promising Clinical Trial Results

Following a notable advancement in clinical trials, shares of Annovis Bio, Inc. (NYSE: ANVS) have experienced a significant uptick. As of the latest market check today, ANVS stock has surged by 30.32%, reaching a price of $10.53. Promising Phase III PD Study Results Buntanetap is safe and effective, according to new findings from Annovis Bio […]